Navigation Links
New drug targets vitamin D receptors in hormone resistant prostate cancers
Date:11/17/2010

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

Results of the phase II(a) clinical trial will be presented at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin today (Thursday). The trial found that when the new drug, inecalcitol, was combined with the existing, current therapy (docetaxel and prednisone) 83% of patients responded to the treatment with a drop in PSA levels of 30% or more within three months of the treatment. PSA levels are used as a marker for tumour activity and successful treatment shrinks cancer, leading to a drop in PSA levels in the blood.

"The PSA responses with this combination are encouraging," said Dr Jacques Medioni, who presented the findings. "It compares favourably with historical data showing that normally 65% of patients respond when treated with docetaxel alone. Furthermore, PSA levels declined by 50% in 67% of patients treated with inecalcitol, and biochemical relapse (when PSA levels start to go up again) did not occur for at least 169 days."

Now inecalcitol is to be tested further in more patients in a larger, phase II(b) clinical trial, which is expected to start in the second quarter of 2011.

Prostate cancer is a chronic disease, usually occurring in men over 50. It is the second most common cancer in men worldwide and an estimated 2.47 million men died from the disease in 2008 worldwide. Initially, male hormones drive the growth of most prostate cancers and so anti-hormonal drugs are effective in stabilising the cancer for several months or years. However, at some point the tumour usually progresses and becomes resistant to anti-hormonal treatments and then it is defined as being hormone-refractory or hormone-resistant prostate cancer (HRPC). Once this happens the p
'/>"/>

Contact: Emma Mason
wordmason@mac.om
ECCO-the European CanCer Organisation
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related medicine news :

1. Drug Targets Faulty Process That Drives Cystic Fibrosis
2. Efforts to combat pneumonia among 15 high-burdened countries fall short of recommended targets
3. Texas Center for Cancer Nanomedicine targets 2 tough cancers
4. Scientists turn a new leaf to discover a compound in daffodils that targets brain cancer
5. Immune systems bare essentials used to speedily detect drug targets
6. Smart drug targets new mutation, dramatically shrinks aggressive sarcoma and lung cancer
7. New program targets research on reducing deaths due to prescription opioid overdose
8. New investigational compound targets pancreatic cancer cells
9. TGen finds therapeutic targets for rare cancer in children
10. MSU targets womens health research with $2.5 million grant
11. Researcher targets gene regulators on link between arsenic, cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... Palo Alto has taken yet another step ... with its recent major long-term solar power commitment. , ... electric power purchase agreements , which together will result in ... photovoltaic electric power per year, which is the equivalent of ... enough power to supply all 65,000+ Palo Alto residents---and then ...
(Date:6/18/2013)... 18, 2013 Seven-year-old Riley Salz of ... autism. He receives 40 hours a week of applied ... from the Center for Autism and Related Disorders (CARD). ... 2008, and has experienced remarkable progress, including learning to ... environment. Riley’s personal journey through autism is now featured ...
(Date:6/18/2013)... have launched an innovative clinical trial, unique in ... a patient,s own stem cells to prevent leg ... , Led by Vik Kashyap, MD, Division ... Center,s Harrington Heart & Vascular Institute and Professor ... of Medicine, the clinical trial is designed to ...
(Date:6/18/2013)... Ill. (PRWEB) June 18, 2013 More than ... are living with HIV/AIDS, according to the Centers for Disease ... know they are infected. In support of National HIV Testing ... Social Security Disability Insurance (SSDI) representation, the CDC and ... testing. , The CDC reports about 50,000 new HIV ...
(Date:6/18/2013)... 2013 myCNAjobs announces the addition of ... articles, and tips to the Caregiver Resources Center. , ... the 10,000+ retiring baby boomers each day, the need ... job resources has never been greater. myCNAjobs, ... community, recently launched the first-ever free resource center for ...
Breaking Medicine News(10 mins):Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 2Health News:Palo Alto Seals the Deal on Major Solar Electric Investments 3Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UH Case Medical Center launches novel clinical trial using stem cells to prevent amputation 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:myCNAjobs Adds New Resources to Growing Caregiver Career Center 2
... plans that give best value for money, study finds , ... aren,t implementing strategies and programs to improve the quality and ... in the Nov. 21 issue of the Journal of ... Health researchers surveyed 609 executives of the largest employers ...
... Inc. (TSX: DDS;,NASDAQ: DDSS) today announced that it ... and Drug Administration (FDA) regarding its appeal of ... through,the Formal Dispute Resolution process. In the response, ... II, Center for Drug Evaluation and,Research has not ...
... Sullivan,s industry research concludes, ,Masimo pulse oximetry is ... sign module clinicians ask for by brand, IRVINE, ... Pulse CO-Oximetry and Read-Through Motion and Low,Perfusion pulse oximetry, ... Best Practices Award, for Pulse Oximetry Leadership -- "ranking,number ...
... 20 NNN Healthcare/Office REIT,Inc. has acquired ... 15, 2007. Northmeadow Medical Center is ... the Atlanta suburb of Roswell,Georgia. Built in ... is,strategically located directly across the street from ...
... 20 CHF,International has been selected as the ... Fund) new Principal Recipient (PR) for,HIV/AIDS prevention, treatment ... awarded an HIV proposal in Round 3 programming., ... years, CHF will be directly responsible for,managing Honduras, ...
... Ga., Nov. 20 Immucor, Inc. (Nasdaq:,BLUD), a ... blood transfusion industry, announced today that Richard A. ... and Chief Financial Officer,effective December 10, 2007. The ... to resign for family reasons but had agreed ...
Cached Medicine News:Health News:Most U.S. Companies Do Little to Boost Worker Health Benefits 2Health News:Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol 2Health News:Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership 2Health News:Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership 3Health News:Masimo Corporation Receives a Frost & Sullivan 2007 Industry Best Practices Award for Pulse Oximetry Leadership 4Health News:NNN Healthcare/Office REIT Acquires Northmeadow Medical Center in Roswell, Georgia 2Health News:NNN Healthcare/Office REIT Acquires Northmeadow Medical Center in Roswell, Georgia 3Health News:CHF International Named Global Fund Principal Recipient in Honduras 2Health News:Immucor, Inc. Appoints New Chief Financial Officer 2
(Date:6/18/2013)... New-generation electronic designs are focused on ... Simultaneously, circuitry is increasing the number of functions ... it performs at. Connecting cables from the active ... such as cameras or detectors, must be small, ... include custom cable designs for high-quality signal and ...
(Date:6/18/2013)... Apama Medical, a privately held medical ... atrial fibrillation technologies, today announced the issuance of ... and Trademark Office (USPTO), titled "Low Profile Electrodes". ... use on expandable structures such as balloons used ... "We are grateful to the NSF SBIR ...
(Date:6/17/2013)... 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... at ENDO 2013, the Endocrine Society,s 95 th ... (synchronize) both melatonin and cortisol rhythms. This effect ... body clock and address the circadian desynchrony which ... (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal ...
Breaking Medicine Technology:Omnetics Circular Connectors Offer Both Micro and Nano Interconnects for Highly Portable Electronic Systems, Meeting the Needs of Designers Looking for Size Reduction Options and Cable Flexibility 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work....
Includes near contrast sensitivity card, calibrated holder, light meter, answer key and instruction manual contrast vision test developed by Arthur P. Ginsburg, Ph.D....
Near PT test card/4 1/2 to 12 PT in spanish & french /5 1/2" X 8....
Card has Jaeger rating and snellen equivalent....
Medicine Products: